AI in Biomarker Discovery: Where the Field Stands in 2026

The Current State of the Field

The field has matured along three axes simultaneously. The technical capabilities have advanced — foundation models adapted to multi-omics data, graph neural networks for protein and pathway analysis, and increasingly sophisticated multi-modal architectures that integrate imaging, genomics, proteomics, and clinical data. The deployment patterns have professionalized — most pharma organizations now have established AI biomarker programs with named leadership, governance integration, and explicit success metrics. The vendor ecosystem has differentiated — a small number of platform vendors dominate enterprise deployments, with a long tail of specialized vendors serving specific therapeutic areas or data modalities.

What has not advanced as rapidly as some 2023-2024 projections suggested is the rate at which AI-discovered biomarkers translate into clinically validated, regulatory-accepted, deployed companion diagnostics. The discovery side of the funnel has accelerated; the translation side has moved more slowly. The result is a growing inventory of AI-flagged biomarker candidates that haven’t yet completed the path to clinical utility — and a growing recognition inside pharma that the discovery investment alone doesn’t capture value without sustained translational investment downstream.

The regulatory posture has shifted in important ways. FDA, EMA, and PMDA have all engaged seriously with AI-derived biomarker evidence in submissions, and the expectations around methodology disclosure, validation rigor, and reproducibility have crystallized. The bar isn’t lower than for traditionally derived biomarkers; in some dimensions it’s higher, because the agencies are still building familiarity with the methodology and want documentation depth that closes any methodological gap.

What’s Actually Working

The use cases delivering measurable value across multiple pharma organizations in 2026 share common characteristics: well-defined biological questions, sufficient and appropriate data, and translation paths that the program designed deliberately rather than assumed.

The patient stratification use case is the most mature and the most consistently value-generating. Pharma organizations that have built durable AI capability for stratification routinely improve trial enrollment efficiency, identify responder subgroups that traditional methods missed, and produce more precise dose-response analyses. The capability has become a competitive baseline rather than a differentiator — organizations without it are increasingly disadvantaged.

Companion diagnostic discovery has become more interesting in 2026 because the regulatory pathway has crystallized. FDA’s evolving posture on AI-derived companion diagnostics — informed by the broader AI/ML medical device guidance — has created clearer expectations for what evidence supports approval. The organizations that engaged early with the methodology now have advantages in submission timing and quality that will compound over the next two to three product cycles.

Multi-omics integration is where the technical frontier is moving fastest. Combining genomics, transcriptomics, proteomics, metabolomics, and increasingly spatial and single-cell data through architectures that genuinely integrate rather than simply concatenate is producing biomarkers that single-modality approaches couldn’t surface. The capability investment is substantial — both in data infrastructure and in talent — but the payoff for organizations with strong execution is real.

The Persistent Challenges

Several challenges that 2023-2024 optimism suggested would resolve quickly have proven more persistent. Naming them honestly helps R&D leaders calibrate expectations and investment.

Reproducibility across cohorts. AI-discovered biomarkers frequently fail to replicate when validated against independent cohorts. The replication failure rate has not improved as rapidly as methodological advances would have predicted. The root causes are well-understood — confounding, batch effects, population shift, overfitting — but they remain operationally difficult to control. Organizations that take reproducibility seriously up front, with multi-cohort validation built into the discovery process from day one, see better translation rates than organizations that treat replication as a downstream concern.

Translation to clinical utility. A statistically significant biomarker is not a clinically useful biomarker. The path from AI signal to validated, deployed clinical utility requires translational work that many AI biomarker programs underinvest in. Programs that pair every discovery investment with a parallel translational investment see materially better outcomes than programs that treat discovery and translation as sequential.

Data quality and integration. Multi-omics integration is technically powerful and operationally difficult. Each data modality has its own quality issues, batch effects, and platform variation. Integrating modalities requires data infrastructure that most pharma organizations are still building. The organizations that have invested years in unified data platforms have significant advantages over those still working with siloed modality-specific systems.

Talent depth. The talent required to do AI biomarker work well — combining computational expertise, biological intuition, clinical context, and regulatory awareness — is scarce and expensive. Most pharma organizations are talent-constrained more than they are technology-constrained, and the talent gap has widened rather than narrowed as the field has grown. Talent investment, including hiring, training, and retention, is the binding constraint for many programs.

Regulatory documentation depth. The regulatory bar for AI-derived biomarker evidence has risen as agencies build familiarity. Organizations that produced submissions in 2023-2024 with relatively light methodology documentation increasingly face follow-up questions and supplemental requests. The depth of documentation required for new submissions in 2026 is higher, and programs that haven’t built the documentation infrastructure are facing material rework.

Technical Landscape and Approaches

The technical landscape has consolidated around a smaller number of dominant approaches, each with distinct strengths and limitations.

Foundation models adapted to biological data are the most prominent recent shift. Models pretrained on large genomic, protein, or biomedical literature corpora and then fine-tuned to specific biomarker discovery tasks are showing strong performance, particularly for tasks where labeled training data is limited. The category includes protein language models, single-cell foundation models, and increasingly multi-modal biomedical foundation models. The technical promise is real; the deployment maturity varies, and operational considerations — model lifecycle, vendor dependence, validation depth — deserve careful attention.

Graph neural networks for protein-protein interaction, pathway analysis, and drug-target interaction continue to mature. The approach captures biological structure that flat representations can’t, and the performance advantages on appropriately framed problems are well-established. The challenge remains the construction and validation of the underlying biological graphs.

Multi-modal integration architectures have advanced significantly, though the gap between research demonstrations and operational deployments remains substantial. The architectures that work robustly in production tend to be more conservative than the cutting-edge research; pharma R&D organizations have learned, sometimes painfully, that production reliability matters more than peak benchmark performance.

Causal inference approaches are receiving growing attention as a complement to predictive ML. The recognition that prediction without causal understanding produces brittle biomarkers has driven investment in methodologies that explicitly address confounding, selection effects, and causal structure. Organizations that integrate causal thinking with ML methodology produce biomarkers that translate better than purely predictive approaches.

Generative approaches for hypothesis generation, candidate biomarker prioritization, and synthetic data augmentation are increasingly part of the toolkit, though their integration into core biomarker workflows remains uneven. The use cases that have proven out are narrower than initial enthusiasm suggested; the use cases that haven’t are still worth tracking but shouldn’t yet bear material program weight.

Regulatory Posture and Validation

The regulatory posture toward AI-derived biomarkers has clarified meaningfully over the past 18 months. FDA’s framework for AI/ML-based medical devices, EMA’s evolving guidance, and the parallel scientific advice processes at PMDA and other agencies have produced a converging set of expectations.

The expectations cluster around several themes. Methodology transparency — the agency wants to understand what was done, with what data, and why. Validation rigor — performance has to be characterized on independent data with appropriate statistical depth. Reproducibility — the methodology, data, and code have to support reproduction, with versioning and provenance documented. Bias and fairness — performance has to be characterized across relevant subpopulations, with mitigation evidence where disparities exist. Lifecycle management — model updates, retraining, and version retirement have to be governed.

The organizations that engage early with regulators see materially better outcomes than organizations that try to optimize submission packages without dialogue. Pre-submission meetings, scientific advice, and engagement with regulator workshops aren’t bureaucratic overhead — they’re the highest-leverage investment in submission success that an AI biomarker program can make.

The Partnership Ecosystem

The vendor and partnership ecosystem has consolidated around several structural categories. Platform vendors providing infrastructure and tooling for AI biomarker work. Specialized vendors with therapeutic area or modality depth — oncology, neurology, imaging-specific platforms. Data providers offering curated multi-omics datasets, real-world evidence, and increasingly federated learning networks. Academic and consortium partners that anchor frontier methodology development.

The partnership decisions that matter most for pharma R&D leaders are about portfolio construction. A pharma organization with strong internal capability and strategic platform partnerships outperforms one with either pure internal build or pure vendor dependency. The construction question is which capabilities to build internally, which to access through partnerships, and how to design the integration so partnerships compound rather than fragment internal capability.

Several partnership patterns are emerging as effective. Foundational platform relationships with two or three strategic vendors that provide infrastructure and tooling. Therapeutic-area-specific specialty partnerships for depth in priority indications. Data partnerships that access curated datasets the pharma organization couldn’t economically build. Academic and consortium relationships that maintain frontier visibility and shape methodology standards. Each pattern has its own diligence requirements, contract considerations, and management overhead.

What R&D Leaders Should Be Doing Now

For pharma R&D leaders evaluating AI biomarker investment in 2026, several priorities consistently differentiate organizations that are positioning well.

1. Audit the discovery-to-translation ratio. Most programs over-invest in discovery and under-invest in translation. Rebalancing toward translation produces materially better outcomes within 18-24 months.
2. Invest in data infrastructure that integrates modalities. The capability advantage from genuine multi-omics integration takes years to build. Starting now compounds; waiting compounds the gap with leaders.
3. Build methodology documentation infrastructure. Regulator expectations are rising. Programs with strong documentation infrastructure can deploy methodologies that would expose programs without it.
4. Engage regulators early and substantively. Pre-submission engagement, scientific advice processes, and workshop participation are leverage that pays back disproportionately.
5. Invest in reproducibility from day one. Multi-cohort validation, versioning discipline, and provenance documentation are easier to build in than to retrofit.
6. Pair AI biomarker programs with translational investment. Discovery without translation produces inventory; the investment ratio determines whether the program produces clinical assets.
7. Develop talent durably. The talent constraint is binding for most programs. Long-term hiring, training, retention, and career path investment matters more than tool selection.
8. Manage the vendor and partnership portfolio deliberately. Concentration risk and fragmentation risk both exist. The portfolio design pays back.

Looking at the Next 24 Months

The next 24 months will likely see several directional shifts that R&D leaders should plan around.

Foundation model approaches will continue to mature, with biology-specific foundation models becoming a baseline capability rather than a frontier. The differentiation will shift from “do you have a foundation model” to “how well do you adapt, validate, and govern your foundation models for specific use cases.”

The regulatory expectations will continue to crystallize, with more specific guidance on validation methodology, documentation depth, and lifecycle management. Organizations that invested in documentation infrastructure now will find themselves comfortably ahead of the bar; organizations that didn’t will be in remediation.

The translation gap — between AI-discovered candidates and validated clinical utility — will become more visible as the cumulative inventory of un-translated candidates grows. Organizations that have systematically invested in translation will see their pipelines move; organizations that haven’t will face uncomfortable questions about return on AI biomarker investment.

The partnership ecosystem will continue consolidating, with several specialty vendors likely acquired and several platform vendors emerging as durable category leaders. Pharma organizations that have made deliberate platform decisions will see their bets pay off; organizations that haven’t will face more difficult vendor transitions than they would have if they had committed earlier.

And the talent landscape will continue tightening. Organizations that built durable talent capability will compound; organizations that relied on contractor relationships and vendor support will find themselves rebuilding under pressure. The talent investment, more than any other single decision, separates the leading 20% from the trailing 80% — and the gap is widening.

The translational infrastructure question

Beyond the directional shifts, one structural question deserves explicit attention from R&D leadership: does the organization have the translational infrastructure to capture value from the AI biomarker investments it’s making? The infrastructure includes assay development capability, clinical validation networks, regulatory engagement capacity, companion diagnostic partnership relationships, and the integrated workflows that move candidates through the path. Organizations with strong infrastructure see a meaningful share of AI-discovered candidates progress; organizations with weak infrastructure accumulate inventory that doesn’t translate.

The infrastructure question deserves the same strategic attention as the discovery investment itself. Many R&D leaders have been substantially more comfortable approving discovery investment — which feels like buying technology — than approving translation infrastructure investment, which feels like funding ongoing capability. The discomfort is understandable but produces predictable underperformance: the discovery investments produce candidates that the underfunded translation infrastructure can’t move. The corrective is to evaluate biomarker investment as a discovery-plus-translation system, not as a discovery investment with translation as a downstream concern.

The portfolio-level discipline

A final consideration that’s becoming more important as the field matures: portfolio-level discipline on AI biomarker investments. Most pharma R&D organizations now have enough AI biomarker activity that managing it as a portfolio rather than as individual programs creates leverage. Portfolio-level questions — how the discovery investments balance across therapeutic areas, where the translation bottlenecks are concentrated, which capabilities are over- or under-resourced relative to the portfolio’s needs — surface optimization opportunities that individual program reviews miss. The R&D leaders who have introduced portfolio-level governance for AI biomarker work consistently report that the discipline pays back disproportionately to its overhead.

Building organizational learning across use cases

An additional discipline differentiates organizations that compound their AI biomarker capability from those that treat each use case as a standalone effort: deliberate organizational learning across use cases. Each AI biomarker use case generates methodology learnings, validation insights, regulatory feedback, and operational lessons that other use cases would benefit from. Organizations that capture and propagate these learnings systematically — through methodology working groups, post-mortem reviews, shared documentation libraries, and rotation of practitioners across use cases — accelerate their second and third use cases relative to their first.

Organizations that don’t capture the learning systematically tend to repeat avoidable mistakes. The replication failure that one team discovered the hard way in their first use case shows up again in another team’s third use case because the learning never moved between teams. The regulator feedback that one program received and incorporated stays in that program’s documentation rather than informing portfolio-wide practice. The compounding advantage that organizational learning creates is real but invisible — and the organizations that don’t invest in it tend not to recognize what they’re foregoing until they encounter peers whose programs are visibly more efficient.

The decision rights question

One organizational question that frequently determines AI biomarker program performance is decision rights — specifically, who has the authority to retire underperforming candidates and which committees can extend them. Programs with crisp decision rights move candidates through the funnel cleanly; candidates that aren’t progressing get retired and resources get redirected. Programs with diffuse decision rights tend to keep candidates alive past the point where they should have been retired, accumulating inventory of zombie candidates that consume management attention without producing value. The decision rights design is mundane but consequential, and R&D leaders who get it right early avoid a class of portfolio drag that’s hard to recover from later.

References